The trajectory of companies tied to Sildenafil's history presents a complex investment scenario . While the initial success generated substantial returns , generic competition have significantly eroded revenue. Investing in related pharmaceutical firms now requires a careful assessment of intellectual property protection , evolving patient trends ,